Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study.
Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study.
复制标题
一种定量针对SARS-CoV-2刺突蛋白S1亚基受体结合域抗体的泛免疫球蛋白测定的表征：一项基于人群的研究。
DOI：
10.3390/jcm9123989
复制
发表时间：
2020-12-09
影响因子：
3.9
通讯作者：
Risch M
中科院分区：
文献类型：
--
作者：
Schaffner A;Risch L;Aeschbacher S;Risch C;Weber MC;Thiel SL;Jüngert K;Pichler M;Grossmann K;Wohlwend N;Lung T;Hillmann D;Bigler S;Bodmer T;Imperiali M;Renz H;Kohler P;Vernazza P;Kahlert CR;Twerenbold R;Paprotny M;Conen D;Risch M
泛免疫球蛋白检测可同时检测针对严重急性呼吸道综合征冠状病毒2型刺突蛋白（S）S1亚基（SARS-CoV-2 S1-RBD IG）受体结合域（RBD）的IgG、IgM和伊加。在这项工作中，我们的目标是评估定量SARS-CoV-2 S1-RBD IG电化学发光免疫分析（ECLIA）的分析，诊断，操作和临床特征。我们的工作是在列支敦士登公国进行的一项基于人群的研究，包括125例临床描述良好并经实验室确认的SARS-CoV-2感染病例和1159例无2019冠状病毒病（COVID-19）证据的个体。SARS-CoV-2病例在症状发作后中位数为48天（四分位距，IQR，43-52）和139天（IQR，129-144）的血清中检测抗体。还用靶向针对非RBD-S1和-S1/S2表位的抗体的其他测定法测试血清。灵敏度为97.6%（95%置信区间，CI，93.2-99.1），而特异性为99.8%（95% CI，99.4-99.9）。从住院患者到有症状的门诊患者和无症状的SARS-CoV-2感染者，抗体水平呈线性下降（p < 0.001）。在SARS-CoV-2感染病例中，吸烟者的抗体水平低于非吸烟者（p = 0.04），发热患者的抗体水平高于非发热患者（p = 0.001）。在SARS-CoV-2感染病例中，Pan-SARS-CoV-2 S1-RBD IG从第一次到第二次随访显著增加（p < 0.001）。相当大比例的没有过去SARS-CoV-2感染证据的个体显示非S1-RBD抗体反应性（248/1159，即，21.4%，95% CI，19.1-23.4）。总之，定量SARS-CoV-2 S1-RBD IG测定提供了有利和持续的测定特征，允许确定临床特征（例如，疾病严重程度、吸烟或发烧）和抗体水平。该检测方法还可以帮助识别具有非S1-RBD特异性抗体的个体，这些抗体对SARS-CoV-2具有潜在的临床交叉反应性。
Pan-immunoglobulin assays can simultaneously detect IgG, IgM and IgA directed against the receptor binding domain (RBD) of the S1 subunit of the spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 S1-RBD Ig). In this work, we aim to evaluate a quantitative SARS-CoV-2 S1-RBD Ig electrochemiluminescence immunoassay (ECLIA) regarding analytical, diagnostic, operational and clinical characteristics. Our work takes the form of a population-based study in the principality of Liechtenstein, including 125 cases with clinically well-described and laboratory confirmed SARS-CoV-2 infection and 1159 individuals without evidence of coronavirus disease 2019 (COVID-19). SARS-CoV-2 cases were tested for antibodies in sera taken with a median of 48 days (interquartile range, IQR, 43–52) and 139 days (IQR, 129–144) after symptom onset. Sera were also tested with other assays targeting antibodies against non-RBD-S1 and -S1/S2 epitopes. Sensitivity was 97.6% (95% confidence interval, CI, 93.2–99.1), whereas specificity was 99.8% (95% CI, 99.4–99.9). Antibody levels linearly decreased from hospitalized patients to symptomatic outpatients and SARS-CoV-2 infection without symptoms (p < 0.001). Among cases with SARS-CoV-2 infection, smokers had lower antibody levels than non-smokers (p = 0.04), and patients with fever had higher antibody levels than patients without fever (p = 0.001). Pan-SARS-CoV-2 S1-RBD Ig in SARS-CoV-2 infection cases significantly increased from first to second follow-up (p < 0.001). A substantial proportion of individuals without evidence of past SARS-CoV-2 infection displayed non-S1-RBD antibody reactivities (248/1159, i.e., 21.4%, 95% CI, 19.1–23.4). In conclusion, a quantitative SARS-CoV-2 S1-RBD Ig assay offers favorable and sustained assay characteristics allowing the determination of quantitative associations between clinical characteristics (e.g., disease severity, smoking or fever) and antibody levels. The assay could also help to identify individuals with antibodies of non-S1-RBD specificity with potential clinical cross-reactivity to SARS-CoV-2.
登录
查看更多内容
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
11.8
作者：
Hanson, Kimberly E.;Caliendo, Angela M.;Mustafa, Reem A.
通讯作者：
Mustafa, Reem A.
DOI：
10.1016/s0140-6736(20)32137-1
发表时间：
2020-11-14
期刊：
Lancet (London, England)
影响因子：
--
作者：
Poland GA;Ovsyannikova IG;Kennedy RB
通讯作者：
Kennedy RB
影响因子：
6.8
作者：
Baron, Rita Christiane;Risch, Lorenz;Risch, Martin
通讯作者：
Risch, Martin
影响因子：
5
作者：
Plebani, Mario;Padoan, Andrea;Sciacovelli, Laura
通讯作者：
Sciacovelli, Laura